iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/20160680
Evaluation of three APBI techniques under NSABP B-39 guidelines - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Dec 3;11(1):3021.
doi: 10.1120/jacmp.v11i1.3021.

Evaluation of three APBI techniques under NSABP B-39 guidelines

Daniel Scanderbeg  1 , Catheryn Yashar, Greg White, Roger Rice, Todd Pawlicki
Affiliations
Comparative Study

Evaluation of three APBI techniques under NSABP B-39 guidelines

Daniel Scanderbeg et al. J Appl Clin Med Phys. .

Abstract

This work compares two accelerated partial breast irradiation modalities, MammoSite brachytherapy and three dimensional conformal radiotherapy (3D-CRT), to a new method, SAVI brachytherapy, following NSABP B-39 guidelines. A total of 21 patients treated at UC San Diego with the SAVI device were evaluated in this comparison. 9 of the 21 patients were eligible for all three modalities and were dosimetrically compared evaluating V90, V150, V200, total target volume, maximum skin, lung, and chestwall/rib dose. The target volumes (PTV_EVAL) differed with SAVI having the least total volume at 59.9 cc vs. 71.5 cc and 351.6 cc for MammoSite and 3D-CRT, respectively. The median V90, V150 and V200 for the three modalities were 97.7%, 25.0 cc, 10.4 cc (SAVI) vs. 97.6%, 23.9 cc, 5.0 cc (MammoSite) vs. 100% (V90 3D-CRT). The maximum dose for SAVI, MammoSite, and 3D-CRT, respectively, relative to the prescribed dose, for the: lung was 80.0%, 150.0%, and 104.9%; for rib 108.8%, 225.0%, and 114.7%: for skin 75.0%, 135.0%, and 108.6%. Comparing modalities, PTV coverage varied between 97.6% - 100.0% with more breast tissue covered by 3D-CRT, as expected, given the differences between external beam and brachytherapy. The maximum lung, skin and rib doses were lowest for the SAVI, highlighting its ability to conform to exclude normal tissues. In offering partial breast radiation, the availability of a variety of techniques allows for maximal patient eligibility, and comparison of individual method pros and cons may guide the most appropriate choice for each patient.

PubMed Disclaimer

Figures

Figure 1
Figure 1
SAVI APBI brachytherapy device: a) collapsed for insertion and removal; b) expanded showing central strut surrounded by peripheral struts.
Figure 2
Figure 2
Single patient with 3 APBI modalities: a) SAVI device; b) MammoSite balloon simulated over the SAVI site; and c) 3D‐CRT plan (preimplant scan).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oliver M, Chen J, Wong E, Van Dyk J, Perera F. A treatment planning study comparing whole breast radiation therapy against conformal, IMRT, and tomotherapy for accelerated partial breast irradiation. Radiother Oncol. 2007; 82(3):317–23. - PubMed
    1. Bovi J, Qi XS, White J, Li XA. Comparison of three accelerated partial breast irradiation techniques: treatment effectiveness based upon biological models. Radiother Oncol. 2007;84(3):226–32. - PubMed
    1. Patel RR, Becker SJ, Das RK, Mackie TR. A dosimetric comparison of accelerated partial breast irradiation techniques: multicatheter interstitial brachytherapy, three‐dimensional conformal radiotherapy, and supine versus prone helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;68(3):935–42. - PubMed
    1. Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early‐stage breast cancer treated with breast‐conserving therapy. Int J Radiat Oncol Biol Phys. 2003;55(12):289–93. - PubMed
    1. Jeruss JS, Vicini FA, Beitsch PD, et al. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma‐in‐situ of the breast. Ann Surg Oncol. 2006;13(7):967–76. - PubMed

MeSH terms